Back to top
more

ICU Medical (ICUI)

(Delayed Data from NSDQ)

$130.06 USD

130.06
173,793

+2.66 (2.09%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $129.18 -0.88 (-0.68%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ICU Medical (ICUI) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 39.84% and 5.54%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ICUI Stock Declines Despite Plans for Offsetting Tariff Impacts

by Zacks Equity Research

ICU Medical unveils a strategic plan to offset new U.S. tariffs, aiming to protect margins and stability amid medtech market volatility and global trade shifts.

Zacks Equity Research

ICUI Stock Gains Following Latest FDA Approvals for Precision IV Pumps

by Zacks Equity Research

ICU Medical aims to enable healthcare systems to customize infusion setups, optimizing device footprint without compromising performance or safety.

Zacks Equity Research

ICU Medical (ICUI) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 42.57% and 3.95%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ResMed Inc. (RMD) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

New Strong Buy Stocks for January 14th

by Zacks Equity Research

BWAY, EE, MATW, BRBR and FMAO have been added to the Zacks Rank #1 (Strong Buy) List on January 14, 2025.

Zacks Equity Research

ICU Medical (ICUI) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 27.20% and 0.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Verano Holdings Corp. (VRNOF) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of -300% and 4.39%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Solventum Q3 Earnings Likely to Reflect Declining Volume Trend

by Zacks Equity Research

SOLV's Q3 performance is likely to have been hurt by below-par revenue growth in several markets, coupled with currency headwinds. Improved pricing might have offset sales decline.

Zacks Equity Research

Strong Demand and Positive Pricing to Drive Baxter's Q3 Earnings

by Zacks Equity Research

BAX's third-quarter results are likely to benefit from a positive pricing impact and new product launches. However, supply-chain issues are likely to have raised expenses in the quarter.

Zacks Equity Research

Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline

by Zacks Equity Research

Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ICU Medical (ICUI) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

ICU Medical (ICUI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will ICU Medical (ICUI) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

ICU Medical (ICUI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

ICU Medical's Stock Rises Despite Bivona Tracheostomy Tube Recall

by Zacks Equity Research

ICUI's Smiths Medical recalls Bivona tracheostomy tubes over a defect that may lead to serious health risks, including airway loss and death.

Zacks Equity Research

Rockwell Medical, Inc. (RMTI) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Zacks Equity Research

ICU Medical, Inc. (ICUI) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

ICU Medical (ICUI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Rockwell Medical, Inc. (RMTI) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Rockwell Medical (RMTI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Zacks Equity Research

ICU Medical, Inc. (ICUI) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

ICU Medical (ICUI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Is ICU Medical (ICUI) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

ICU Medical (ICUI) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 59.18% and 7%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Baxter International (BAX) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of 3.03% and 1.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Brainsway (BWAY): Can Its 9.3% Jump Turn into More Strength?

by Zacks Equity Research

Brainsway (BWAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Implied Volatility Surging for ICU Medical (ICUI) Stock Options

by Zacks Equity Research

Investors need to pay close attention to ICU Medical (ICUI) stock based on the movements in the options market lately.